Moleculin Biotech, Inc. Gains 35.96%

Tue, Feb 02, 2021 at 05:30 PM

Moleculin Biotech, Inc. (MBRX:NASDAQ) rocketted at $6.39, representing a gain of 36%. On Mon 01 Feb 21, MBRX:NASDAQ touched a New 2-Week High of $4.7. The stock appeared on our News Catalysts scanner on Tue 02 Feb 21 at 05:06 PM in the 'PUBLIC OFFERING' category. From Tue 19 Jan 21, the stock recorded 22.22% Up Days and 40.00% Green Days

About Moleculin Biotech, Inc. (MBRX:NASDAQ)

Moleculin Biotech Inc is a preclinical stage pharmaceutical company. The company is engaged in the development of anti-cancer drug candidates. Its drug development technologies include liposomal Annamycin, WP1122 and WP1066.

Top 10 Gainers:

Cassava Sciences, Inc. (SAVA:NASDAQ), 141.15%
Ocugen, Inc. (OCGN:NASDAQ), 80.11%
HOL (HOL:NASDAQ), 57.09%
Vaxart, Inc. (VXRT:NASDAQ), 49.84%
Aeterna Zentaris Inc. (AEZS:NASDAQ), 42.86%
Lizhi Inc. (LIZI:NASDAQ), 41.37%
NTN Buzztime, Inc. (NTN:NYSEMKT), 36.91%
Moleculin Biotech, Inc. (MBRX:NASDAQ), 35.96%
SELLAS Life Sciences Group, Inc. (SLS:NASDAQ), 34.1%
The9 Limited (NCTY:NASDAQ), 33.09%